SGLN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SGLN pulled ahead of the other in Year 1
Combined, SGLN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SGLN + ABBV for your $10,000?
Surgline International, Inc. sources and sells medical and surgical products. It offers a range of surgical instruments, including scissors, forceps, basket punches, reamers, and pulse lavages. The company also provides surgical sets, such as hand and foot, and hips and small fragments; spine products consisting of ALIF systems, anterior cervical plates, PLIF systems, TLIF systems, cervical PEEK IBFDs, and pedicle screw systems; drill system and power tools comprising cordless and pneumatic drills, chucks, sleeves, saws, hoes, charges, and batteries. In addition, it offers emergency removal devices for broken screws and implant removal; a range of endoscopes; surgical burs and blades; and medical, surgical, and dental disposables. The company sells its products under the Surg brand. It serves acute care hospitals, ambulatory surgery centers, physicians, dentists, urgent care centers, and insurers, as well as others. The company was formerly known as China Nuvo Solar Energy, Inc. and changed its name to Surgline International, Inc. in October 2011. Surgline International, Inc. is based in Newport Beach, California.
Full SGLN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.